Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Clinical and Vaccine Immunology : CVI
|
October 31, 2014
Systems immunology reveals markers of susceptibility to West Nile virus infection
Feng Qian, Gautam Goel, Hailong Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Magdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Human Pathology
|
April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Luc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 10, 2017
Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During Pregnancy
Jana Blazkova, Sarthak Gupta, Yudong Liu, et al.
Blood
|
January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
Magdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Nature Medicine
|
January 17, 2017
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states
David Furman, Junlei Chang, Lydia Lartigue, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood Advances
|
July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
Jonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Clinical and Vaccine Immunology : CVI
|
October 31, 2014
Systems immunology reveals markers of susceptibility to West Nile virus infection
Feng Qian, Gautam Goel, Hailong Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Magdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Human Pathology
|
April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Luc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 10, 2017
Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During Pregnancy
Jana Blazkova, Sarthak Gupta, Yudong Liu, et al.
Blood
|
January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
Magdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Nature Medicine
|
January 17, 2017
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states
David Furman, Junlei Chang, Lydia Lartigue, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood Advances
|
July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
Jonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Page
of 5